Howard Takiff

Dr. Howard Takiff

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Tuberculosis
Verified
Journal Article
Closed access
AEAmel Kevin Alame Emane
Amel Kevin Alame Emane
XGXujun Guo
Xujun Guo
HTHoward Takiff
Howard Takiff
SLShengyuan Liu
Shengyuan Liu

1 September 2015 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
HTHoward Takiff
Howard Takiff
OFOscar Feo
Oscar Feo

1 May 2014 in mBio
Verified
Journal Article
Open access
CCClaudia Cortesia
Claudia Cortesia
CVCatherine Vilchèze
Catherine Vilchèze
ABAudrey Bernut
Audrey Bernut
WCWhendy Contreras
Whendy Contreras
KGKeyla Gómez
Keyla Gómez
HTHoward Takiff
Howard Takiff
Effective and economical mycobactericidal disinfectants are needed to kill both Mycobacterium tuberculosis and non- M. tuberculosis mycobacteria. We found that acetic acid (vinegar) efficiently kills M. tuberculosis after 30 min of exposure to a 6% acetic acid solution. The activity is not due to pH alone, and propionic acid also appears to be bactericidal. M. bolletii and M. massiliense nontuberculous mycobacteria were more resistant, although a 30-min exposure to 10% acetic acid resulted in at least a 6-log 10 reduction of viable bacteria. Acetic acid (vinegar) is an effective mycobactericidal disinfectant that should also be active against most other bacteria. These findings are consistent with and extend the results of studies performed in the early and mid-20th century on the disinfectant capacity of organic acids. IMPORTANCE Mycobacteria are best known for causing tuberculosis and leprosy, but infections with nontuberculous mycobacteria are an increasing problem after surgical or cosmetic procedures or in the lungs of cystic fibrosis and immunosuppressed patients. Killing mycobacteria is important because Mycobacterium tuberculosis strains can be multidrug resistant and therefore potentially fatal biohazards, and environmental mycobacteria must be thoroughly eliminated from surgical implements and respiratory equipment. Currently used mycobactericidal disinfectants can be toxic, unstable, and expensive. We fortuitously found that acetic acid kills mycobacteria and then showed that it is an effective mycobactericidal agent, even against the very resistant, clinically important Mycobacterium abscessus complex. Vinegar has been used for thousands of years as a common disinfectant, and if it can kill mycobacteria, the most disinfectant-resistant bacteria, it may prove to be a broadly effective, economical biocide with potential usefulness in health care settings and laboratories, especially in resource-poor countries.

1 December 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
HTHoward Takiff
Howard Takiff
EGElba Guerrero
Elba Guerrero
While fluoroquinolones (FQs) have been successful in helping cure multidrug-resistant tuberculosis (MDR TB), studies in mice have suggested that if used as first-line agents they might reduce the duration of therapy required to cure drug-sensitive TB. The results of phase II trials with FQs as first-line agents have been mixed, but in at least three studies where moxifloxacin substituted for ethambutol, there was an increase in the early percentage of sputa that converted to negative for bacilli. Phase III trials are in progress to test the effectiveness of 4-month FQ-containing regimens, but there is concern that the widespread use of FQs for other infections could engender a high prevalence of FQ-resistant TB. However, several studies suggest that despite wide FQ use, the prevalence of FQ-resistant TB is low, and the majority of the resistance is low-level. The principal risk for resistance may be when FQs are used to treat nonspecific respiratory symptoms that are in fact TB, so curtailing this use of FQs could reduce the development of resistance and also the delays in TB diagnosis and treatment that have been documented when an FQ is given in this setting. While the future of FQs as first-line therapy will likely depend upon the results of the ongoing phase III trials, if they are to be effectively employed in high-TB-burden regions their use for community-acquired pneumonias should be restricted, the prevalence of FQ-resistant TB should be monitored, and the cost of the treatment should be comparable to that of current standard drug regimens.

15 August 2014 in Microbiology Spectrum
Verified
Journal Article
Closed access
CMClaudine Mayer
Claudine Mayer
HTHoward Takiff
Howard Takiff
The fluoroquinolones (FQs) are synthetic antibiotics effectively used for curing patients with multidrug-resistant tuberculosis (TB). When a multidrug-resistant strain develops resistance to the FQs, as in extensively drug-resistant strains, obtaining a cure is much more difficult, and molecular methods can help by rapidly identifying resistance-causing mutations. The only mutations proven to confer FQ resistance in M. tuberculosis occur in the FQ target, the DNA gyrase, at critical amino acids from both the gyrase A and B subunits that form the FQ binding pocket. GyrA substitutions are much more common and generally confer higher levels of resistance than those in GyrB. Molecular techniques to detect resistance mutations have suboptimal sensitivity because gyrase mutations are not detected in a variable percentage of phenotypically resistant strains. The inability to find gyrase mutations may be explained by heteroresistance: bacilli with a resistance-conferring mutation are present only in a minority of the bacterial population (>1%) and are therefore detected by the proportion method, but not in a sufficient percentage to be reliably detected by molecular techniques. Alternative FQ resistance mechanisms in other bacteria—efflux pumps, pentapeptide proteins, or enzymes that inactivate the FQs—have not yet been demonstrated in FQ-resistant M. tuberculosis but may contribute to intrinsic levels of resistance to the FQs or induced tolerance leading to more frequent gyrase mutations. Moxifloxacin is currently the best anti-TB FQ and is being tested for use with other new drugs in shorter first-line regimens to cure drug-susceptible TB.

20 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
QLQingyun Liu
Qingyun Liu
HLHaican Liu
Haican Liu
LSLi Shi
Li Shi
MGMingyu Gan
Mingyu Gan
XZXiuqin Zhao
Xiuqin Zhao
QGQian Gao
Qian Gao
Significance: The global distribution of different Mtb lineages is very structured, with a few lineages that are globally widespread, whereas many others are restricted to particular geographic regions. Although local adaptation has been a favored model for explaining the sympatric relationship between the bacteria and host in these geographic regions, this has been difficult to study. Human migration has led to intermixing of ethnicities and has disturbed the bacterial population structure, thereby masking the putative genetic determinants that may have evolved from selection pressures in a given region. Here, by analyzing the genomes of hundreds of Mtb strains sampled from the relatively isolated population of Tibetan, we provide genetic evidence that Mtb can evolve to adapt to local populations and environments.